LSID

Editas Medicine Announces First Quarter 2024 Results and Business Updates

Retrieved on: 
星期三, 五月 8, 2024
Rubius, CRISPR, Research, Paratriathlon, University of California, Intellectual property, CAFC, SCD, BMY, Editas Medicine, Gene editing, Adolescence, Medicine, Leber congenital amaurosis, Bristol Myers Squibb, Therapy, Vertex Pharmaceuticals, Cas9, Guide, Change, LSID, Emmanuelle, Blas, Public expenditure, Human, University of Vienna, Collaboration, CVC, Bluebird bio, TDT, Sale, Cancer, Cell, Quality, Senior, Patent, Patient, Liver, Gene, Society, Pharmaceutical industry

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today reported financial results for the first quarter 2024 and provided business updates.

Key Points: 
  • CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today reported financial results for the first quarter 2024 and provided business updates.
  • “We made significant progress in all three pillars of our strategy this quarter, including reni-cel, in vivo, and business development, including intellectual property,” commented Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine.
  • ET to provide and discuss a corporate update and financial results for the first quarter of 2024.
  • To access the call, please dial 1-877-407-0989 (domestic) or 1-201-389-0921 (international) and ask for the Editas Medicine earnings call.

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Retrieved on: 
星期一, 四月 22, 2024
Guide, LSID, Abstract, Research, Editas Medicine, Abstract (summary), Gene editing, RNA, Cell, Medicine, Gene, Society, Vaccine

The Company is presenting pre-clinical data to support its development of transformative in vivo gene editing medicines.

Key Points: 
  • The Company is presenting pre-clinical data to support its development of transformative in vivo gene editing medicines.
  • Editas Medicine presentations at ASGCT include:
    Pre-clinical data demonstrating AsCas12a gRNA modifications that enable high-potency gene editing in multiple cell types and improve gene editing outcomes in vivo, enabling the development of in vivo gene editing medicines.
  • Research on identifying potent large serine recombinases (LSRs) as a foundation to develop novel in vivo gene editing technologies for whole gene knock-in, expanding potential in vivo gene editing targets for developing medicines.
  • These in vivo data are an important step towards confirming in vivo proof of concept by the end of the year.”
    The complete list of Editas Medicine presentations is below.

OhioHealth and MedSpeed Partner to Reduce Greenhouse Gas Emissions

Retrieved on: 
星期四, 六月 29, 2023
Partnership, OhioHealth, LSID, OH, GHG, Natural Resources, EVS, Organization, Blood, City, Transport, Health, Environment, Renewable energy

COLUMBUS, Ohio and ELMHURST, Ill., June 29, 2023 /PRNewswire-PRWeb/ -- In support of OhioHealth's pledge to reduce greenhouse gas (GHG) emissions as an ongoing action to decarbonize the healthcare sector, its same-day logistics service provider, MedSpeed, is deploying electric vehicles (EVs) to service OhioHealth's network.

Key Points: 
  • COLUMBUS, Ohio and ELMHURST, Ill., June 29, 2023 /PRNewswire-PRWeb/ -- In support of OhioHealth's pledge to reduce greenhouse gas (GHG) emissions as an ongoing action to decarbonize the healthcare sector, its same-day logistics service provider, MedSpeed, is deploying electric vehicles (EVs) to service OhioHealth's network.
  • "The goal of our greenhouse gas emissions pledge is to reduce our emissions by 50 percent by 2030 and achieve zero emissions by 2050," said OhioHealth Chief Administrative Officer, Johnni Beckel.
  • "Supported by partnerships with Smart Columbus and Electrification Coalition, OhioHealth and MedSpeed conducted an assessment of the routes that were eligible for electrification," said OhioHealth Advisor of Sustainability Allegra Wiesler.
  • Since forming the partnership between OhioHealth and MedSpeed a decade ago, the healthcare provider has grown significantly.